Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 328

Similar articles for PubMed (Select 20383201)

1.

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.

Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS, Whang YE.

Oncogene. 2010 Jun 3;29(22):3208-16. doi: 10.1038/onc.2010.103. Epub 2010 Apr 12.

2.

Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation.

Mahajan NP, Liu Y, Majumder S, Warren MR, Parker CE, Mohler JL, Earp HS, Whang YE.

Proc Natl Acad Sci U S A. 2007 May 15;104(20):8438-43. Epub 2007 May 9.

3.

Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer.

Yang JC, Ok JH, Busby JE, Borowsky AD, Kung HJ, Evans CP.

Cancer Res. 2009 Jan 1;69(1):151-60. doi: 10.1158/0008-5472.CAN-08-0442.

4.

Src controls castration recurrence of CWR22 prostate cancer xenografts.

Su B, Gillard B, Gao L, Eng KH, Gelman IH.

Cancer Med. 2013 Dec;2(6):784-92. doi: 10.1002/cam4.144. Epub 2013 Oct 11.

5.

Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.

Serrels A, Macpherson IR, Evans TR, Lee FY, Clark EA, Sansom OJ, Ashton GH, Frame MC, Brunton VG.

Mol Cancer Ther. 2006 Dec;5(12):3014-22. Epub 2006 Dec 5.

6.

Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity.

Mahajan K, Challa S, Coppola D, Lawrence H, Luo Y, Gevariya H, Zhu W, Chen YA, Lawrence NJ, Mahajan NP.

Prostate. 2010 Sep 1;70(12):1274-85. doi: 10.1002/pros.21163.

7.

Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.

Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M.

Cancer Res. 2004 Oct 1;64(19):7156-68.

8.

Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.

Migliaccio A, Di Domenico M, Castoria G, Nanayakkara M, Lombardi M, de Falco A, Bilancio A, Varricchio L, Ciociola A, Auricchio F.

Cancer Res. 2005 Nov 15;65(22):10585-93.

9.

Regulation of androgen receptor activity by tyrosine phosphorylation.

Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, Nesheiwat I, Kong X, Melamed J, Handratta VD, Njar VC, Brodie AM, Yu LR, Veenstra TD, Chen H, Qiu Y.

Cancer Cell. 2006 Oct;10(4):309-19. Erratum in: Cancer Cell. 2007 Jan;11(1):97.

11.

Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo.

Goc A, Al-Husein B, Katsanevas K, Steinbach A, Lou U, Sabbineni H, DeRemer DL, Somanath PR.

Oncotarget. 2014 Feb 15;5(3):775-87.

12.

Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and src-dependent tyrosine phosphorylation of RSK2 at Tyr-529.

Kang S, Dong S, Guo A, Ruan H, Lonial S, Khoury HJ, Gu TL, Chen J.

J Biol Chem. 2008 Feb 22;283(8):4652-7. Epub 2007 Dec 21.

13.

Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells.

Dai B, Chen H, Guo S, Yang X, Linn DE, Sun F, Li W, Guo Z, Xu K, Kim O, Kong X, Melamed J, Qiu S, Chen H, Qiu Y.

Cancer Res. 2010 Jul 1;70(13):5587-96. doi: 10.1158/0008-5472.CAN-09-4610. Epub 2010 Jun 22.

14.

The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.

Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, Hung MC, Siddik ZH, Bast RC Jr.

J Natl Cancer Inst. 2011 Sep 21;103(18):1403-22. doi: 10.1093/jnci/djr280. Epub 2011 Aug 2.

15.

Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.

Lee YC, Huang CF, Murshed M, Chu K, Araujo JC, Ye X, deCrombrugghe B, Yu-Lee LY, Gallick GE, Lin SH.

Oncogene. 2010 Jun 3;29(22):3196-207. doi: 10.1038/onc.2010.73. Epub 2010 Mar 15.

16.

Ack1-mediated androgen receptor phosphorylation modulates radiation resistance in castration-resistant prostate cancer.

Mahajan K, Coppola D, Rawal B, Chen YA, Lawrence HR, Engelman RW, Lawrence NJ, Mahajan NP.

J Biol Chem. 2012 Jun 22;287(26):22112-22. doi: 10.1074/jbc.M112.357384. Epub 2012 May 7.

17.

Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.

Gregory CW, Whang YE, McCall W, Fei X, Liu Y, Ponguta LA, French FS, Wilson EM, Earp HS 3rd.

Clin Cancer Res. 2005 Mar 1;11(5):1704-12.

18.

Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells.

Yang X, Guo Z, Sun F, Li W, Alfano A, Shimelis H, Chen M, Brodie AM, Chen H, Xiao Z, Veenstra TD, Qiu Y.

J Biol Chem. 2011 Oct 14;286(41):36152-60. doi: 10.1074/jbc.M111.265124. Epub 2011 Aug 30.

19.

Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK.

Lee LF, Louie MC, Desai SJ, Yang J, Chen HW, Evans CP, Kung HJ.

Oncogene. 2004 Mar 18;23(12):2197-205.

PMID:
14767470
20.

Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.

Luo FR, Barrett YC, Yang Z, Camuso A, McGlinchey K, Wen ML, Smykla R, Fager K, Wild R, Palme H, Galbraith S, Blackwood-Chirchir A, Lee FY.

Cancer Chemother Pharmacol. 2008 Nov;62(6):1065-74. doi: 10.1007/s00280-008-0699-5. Epub 2008 Feb 27.

PMID:
18301894
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk